- Home
- SYF vs MRNA Comparison
SYF vs MRNA Comparison
Compare SYF & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYF
- MRNA
- Stock Information
- Founded
- SYF 1932
- MRNA 2010
- Country
- SYF United States
- MRNA United States
- Employees
- SYF N/A
- MRNA N/A
- Industry
- SYF Finance: Consumer Services
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SYF Finance
- MRNA Health Care
- Exchange
- SYF Nasdaq
- MRNA Nasdaq
- Market Cap
- SYF 19.4B
- MRNA 16.0B
- IPO Year
- SYF N/A
- MRNA 2018
- Fundamental
- Price
- SYF $61.41
- MRNA $35.53
- Analyst Decision
- SYF Buy
- MRNA Hold
- Analyst Count
- SYF 22
- MRNA 20
- Target Price
- SYF $66.45
- MRNA $59.65
- AVG Volume (30 Days)
- SYF 4.3M
- MRNA 13.6M
- Earning Date
- SYF 01-28-2025
- MRNA 02-14-2025
- Dividend Yield
- SYF 1.63%
- MRNA N/A
- EPS Growth
- SYF 64.74
- MRNA N/A
- EPS
- SYF 8.55
- MRNA N/A
- Revenue
- SYF $9,392,000,000.00
- MRNA $3,236,000,000.00
- Revenue This Year
- SYF N/A
- MRNA N/A
- Revenue Next Year
- SYF $7.81
- MRNA $22.19
- P/E Ratio
- SYF $7.18
- MRNA N/A
- Revenue Growth
- SYF 22.58
- MRNA N/A
- 52 Week Low
- SYF $39.67
- MRNA $29.25
- 52 Week High
- SYF $70.93
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- SYF 33.47
- MRNA 48.60
- Support Level
- SYF $63.31
- MRNA $32.78
- Resistance Level
- SYF $65.97
- MRNA $36.98
- Average True Range (ATR)
- SYF 2.09
- MRNA 2.50
- MACD
- SYF -0.53
- MRNA 0.30
- Stochastic Oscillator
- SYF 4.72
- MRNA 66.81
About SYF Synchrony Financial
Synchrony Financial, originally a spinoff of GE Capital's retail financing business, is the largest provider of private-label credit cards in the United States by both outstanding receivables and purchasing volume. Synchrony partners with other firms to market its credit products in their physical stores as well as on their websites and mobile applications. Synchrony operates through three segments: retail card (private-label and co-branded general-purpose credit cards), payment solutions (promotional financing for large ticket purchases), and CareCredit (financing for elective healthcare procedures).
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.